Genotype, Mortality, Morbidity, and Outcomes of 3β-Hydroxysteroid Dehydrogenase Deficiency in Algeria - PubMed (original) (raw)
Genotype, Mortality, Morbidity, and Outcomes of 3β-Hydroxysteroid Dehydrogenase Deficiency in Algeria
Asmahane Ladjouze et al. Front Endocrinol (Lausanne). 2022.
Abstract
Background: 3β-hydroxysteroid dehydrogenase 2 (3βHSD2) deficiency is a rare form of congenital adrenal hyperplasia (CAH), with fewer than 200 cases reported in the world literature and few data on outcomes.
Patients and methods: We report a mixed longitudinal and cross-sectional study from a single Algerian center between 2007 and 2021. Virilization and under-masculinization were assessed using Prader staging and the external masculinization score (EMS), pubertal development staged according to the system of Tanner. Adrenal steroids were measured using mass spectrophotometry (LC-MS/MS). A genetic analysis of HSD3B2 was performed using Sanger sequencing.
Results: A 3βHSD2 defect was confirmed in 6 males and 8 females from 10 families (8 consanguineous), with p.Pro222Gln mutation in all but two siblings with a novel deletion: c.453_464del or p.(Thr152_Pro155del). Probable 3βHSD2 deficiency was diagnosed retrospectively in a further 6 siblings who died, and in two patients from two other centers. In the genetically confirmed patients, the median (range) age at presentation was 20 (0-390) days, with salt-wasting (n = 14) and genital anomaly (n = 10). The Prader stage for female patients was 2 (1-2) with no posterior fusion of the labia. The EMS for males was 6 (3-9). Median (range) values at diagnosis for 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEA-S), and 17-hydroxypregnenolone (17OHPreg) were elevated: 73.7 (0.37-164.3) nmol/L; 501.2(9.4-5441.3) nmol/L, and 139.7 (10.9-1500) nmol/l (NB >90 nmol/L diagnostic of 3βHSD2 defect). Premature pubarche was observed in four patients (3F:1M). Six patients (5F:1M) entered puberty spontaneously, aged 11 (5-13) years in 5 girls and 11.5 years in one boy. Testicular adrenal rest tumors were found in three boys. Four girls reached menarche at 14.3 (11-14.5) years, with three developing adrenal masses (surgically excised in two) and polycystic ovary syndrome (PCOS), with radiological evidence of ovarian adrenal rest tumor in one. The median IQ was 90 (43-105), >100 in only two patients and <70 in three.
Conclusions: The prevalence of 3βHSD2 deficiency in Algeria appears high, with p.Pro222Gln being the most frequent mutation. Mortality is also high, with significant morbidity from adrenal tumors and PCOS in adolescence and an increased risk of learning disability. The finding of adrenal tumors in older patients with 3βHSD2 indicates under-replacement, requiring effective hydrocortisone and fludrocortisone treatment rather than surgical removal.
Keywords: 3-β hydroxysteroid dehydrogenase deficiency; 3βHSD2; HSD3B2; adrenal rest tumors; congenital adrenal hyperplasia; newborn screening; polycystic ovary syndrome.
Copyright © 2022 Ladjouze, Donaldson, Plotton, Djenane, Mohammedi, Tardy-Guidollet, Mallet, Boulesnane, Bouzerar, Morel and Roucher-Boulez.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Figure 1
Family tree of 10 Algerian families (8 consanguineous) with a) 3βHSD2 deficiency (individuals shown as hatched circles or squares); and b) an unclassified severe learning disability syndrome (affected individuals shown as speckled circles or squares). A HSD3B2: p.Pro222Gln mutation was found in 9 families (diagonal hatching), while Family B shows a novel HSD3B2: p.Thr152_Pro155del mutation (horizontal hatching). Of 42 children born to the 10 families, 3βHSD2 deficiency was genetically proven in 18 (2 deaths) and suspected on clinical grounds in twins from Family E with neonatal death from salt-wasting.
Figure 2
(A–C) Appearance of external genitalia in two siblings from family E with 3βHSD2 deficiency due to a p.P222Q mutation, showing virilization with clitoromegaly and pubic hair in the sister, E II-8 (A) and under-masculinisation in the brother, EII-9 (B, C).
Figure 3
Characteristics of the p.P222Q mutation of the HSD3B2 gene [From Moisan et al, 1999 (27)] —reproduced by kind permission of Oxford University Press).
Figure 4
(A, B) Abdominal MRI scan in a 16-year-old with 3βHSD2 deficiency (Patient B II-1). Axial and coronal sections demonstrate a large left-sided adrenal tumor measuring 63 × 52 × 51 mm. The lesion shows central cystic degeneration and is pushing the kidney downwards. RK, right kidney; LK, left kidney; S, spleen; AT, adrenal tumor.
Figure 5
(A–C) Histology of adrenal tumor from patient G II-1 following surgical removal showing (A) fibrous capsule with an underlying neoplasm containing hemorrhagic foci, no vascular or capsular invasion; (B) tumor composed of cells arranged in nests and cords separated by vasculature and lymphoid tissue; and (C) higher magnification showing that the cells have distinct boundaries and clear cytoplasm with monomorphic nuclei and foci of oncocytic metaplasia. There is hyperchromasia of the nuclei and apoptosis. C, capsule; H, hemorrhagic focus; CNI, cords, nests and islands of tumor.
Similar articles
- Approach of Heterogeneous Spectrum Involving 3beta-Hydroxysteroid Dehydrogenase 2 Deficiency.
Nicola AG, Carsote M, Gheorghe AM, Petrova E, Popescu AD, Staicu AN, Țuculină MJ, Petcu C, Dascălu IT, Tircă T. Nicola AG, et al. Diagnostics (Basel). 2022 Sep 7;12(9):2168. doi: 10.3390/diagnostics12092168. Diagnostics (Basel). 2022. PMID: 36140569 Free PMC article. Review. - Revisiting Classical 3β-hydroxysteroid Dehydrogenase 2 Deficiency: Lessons from 31 Pediatric Cases.
Guran T, Kara C, Yildiz M, Bitkin EC, Haklar G, Lin JC, Keskin M, Barnard L, Anik A, Catli G, Guven A, Kirel B, Tutunculer F, Onal H, Turan S, Akcay T, Atay Z, Yilmaz GC, Mamadova J, Akbarzade A, Sirikci O, Storbeck KH, Baris T, Chung BC, Bereket A. Guran T, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa022. doi: 10.1210/clinem/dgaa022. J Clin Endocrinol Metab. 2020. PMID: 31950145 - Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping.
Mermejo LM, Elias LL, Marui S, Moreira AC, Mendonca BB, de Castro M. Mermejo LM, et al. J Clin Endocrinol Metab. 2005 Mar;90(3):1287-93. doi: 10.1210/jc.2004-1552. Epub 2004 Dec 7. J Clin Endocrinol Metab. 2005. PMID: 15585552 - Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency.
Simard J, Moisan AM, Morel Y. Simard J, et al. Semin Reprod Med. 2002 Aug;20(3):255-76. doi: 10.1055/s-2002-35373. Semin Reprod Med. 2002. PMID: 12428206 Review.
Cited by
- Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone and androgen receptors-mediated transactivation.
Yazawa T, Watanabe Y, Yokohama Y, Imamichi Y, Hasegawa K, Nakajima KI, Kitano T, Ida T, Sato T, Islam MS, Umezawa A, Takahashi S, Kato Y, Jahan S, Kawabe JI. Yazawa T, et al. Front Endocrinol (Lausanne). 2024 Oct 2;15:1480722. doi: 10.3389/fendo.2024.1480722. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39415787 Free PMC article. - Landscape of Adrenal Tumours in Patients with Congenital Adrenal Hyperplasia.
Carsote M, Gheorghe AM, Nistor C, Trandafir AI, Sima OC, Cucu AP, Ciuche A, Petrova E, Ghemigian A. Carsote M, et al. Biomedicines. 2023 Nov 16;11(11):3081. doi: 10.3390/biomedicines11113081. Biomedicines. 2023. PMID: 38002081 Free PMC article. Review. - Identification of a novel candidate HSD3B2 gene variant for familial hypospadias by whole-exome sequencing.
Almaramhy HH, Abdul Samad F, Al-Harbi G, Zaytuni D, Imam SN, Masoodi T, Shamsi MB. Almaramhy HH, et al. Front Genet. 2023 Jun 13;14:1106933. doi: 10.3389/fgene.2023.1106933. eCollection 2023. Front Genet. 2023. PMID: 37384334 Free PMC article. - Genetic Testing for a Patient with Suspected 3 Beta-Hydroxysteroid Dehydrogenase Deficiency: A Case of Unreported Genetic Variants.
Menegatti E, Tessaris D, Barinotti A, Matarazzo P, Einaudi S. Menegatti E, et al. J Clin Med. 2022 Sep 29;11(19):5767. doi: 10.3390/jcm11195767. J Clin Med. 2022. PMID: 36233635 Free PMC article. - Approach of Heterogeneous Spectrum Involving 3beta-Hydroxysteroid Dehydrogenase 2 Deficiency.
Nicola AG, Carsote M, Gheorghe AM, Petrova E, Popescu AD, Staicu AN, Țuculină MJ, Petcu C, Dascălu IT, Tircă T. Nicola AG, et al. Diagnostics (Basel). 2022 Sep 7;12(9):2168. doi: 10.3390/diagnostics12092168. Diagnostics (Basel). 2022. PMID: 36140569 Free PMC article. Review.
References
- Morel Y, Roucher F, Plotton I, Simard J, Coll M. 3β-Hydroxysteroid Dehydrogenase Deficiency. In: Genetic Steroid Disorders. Elsevier. p. 99–110. doi: 10.1016/B978-0-12-416006-4.00008-9 - DOI
- Simard J, Ricketts ML, Moisan AM, Tardy V, Peter M, Van Vliet G, et al. . A New Insight Into the Molecular Basis of 3beta-Hydroxysteroid Dehydrogenase Deficiency(2000) (Accessed February 15, 2015). - PubMed
- Zerah M, Rhéaume E, Mani P, Schram P, Simard J, Labrie F, et al. . No Evidence of Mutations in the Genes for Type I and Type II 3 Beta-Hydroxysteroid Dehydrogenase (3 Beta HSD) in Nonclassical 3 Beta HSD Deficiency. J Clin Endocrinol Metab (1994) 79:1811–7. doi: 10.1210/JCEM.79.6.7989489 - DOI - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical